The ability of GLP-1 agonists to shift the microbial balance toward a healthier profile underscores their potential to disrupt the harmful cycle of obesity-induced gut dysbiosis and inflammation. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.